Preclinical data from a study conducted by Enlivex Therapeutics in collaboration with Yale Cancer Center showed substantial and statistically significant improvements in survival benefit, survival duration, and tumor burden reduction in ovarian cancer when Allocetra was combined with an anti-PD1 checkpoint inhibitor.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe